Brief: Tango Therapeutics Announces Discontinuation Of Tng348 Program
23/05/2024 12:03
Tango Therapeutics Inc TNGX.O :
* TANGO THERAPEUTICS ANNOUNCES DISCONTINUATION OF TNG348
PROGRAM
* TANGO THERAPEUTICS INC - CASH RUNWAY EXTENDED INTO 2027,
PRMT5
AND COREST CLINICAL PROGRAMS REMAIN ON TRACK
* TANGO THERAPEUTICS INC - PHASE 1/2 CLINICAL TRIAL OF
TNG348, A
USP1 INHIBITOR, IS BEING TERMINATED DUE TO TOXICITY OBSERVED IN
INITIAL STUDY COHORTS
Source text for Eikon: ID:nBwbDdG4ca
Further company coverage: TNGX.O
Recent news on Tango Therapeutics
See all newsBrief: Tango Therapeutics, Inc. Approved A Strategic Reprioritization Of The Company’S Research And Development Activities
Brief: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Tango Therapeutics - Files Prospectus To Sell Up To $400 Million In Common Stock
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,